 ADC Therapeutics SA NYSE:ADCT, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced today that interim clinical data on loncastuximab tesirine Lonca, formerly ADCT-402 will be presented in an oral presentation and e-Poster at the virtual 25th Congress of the European Hematology Association EHA25. 